VIM
REGN icon

Vinva Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Vinva Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.1M Buy
14,862
+972
+7% +$744K 0.14% 166
2025
Q4 		$10.8M Buy
13,890
+5,115
+58% +$3.47M 0.13% 155
2025
Q3 		$4.92M Buy
8,775
+2,093
+31% +$1.18M 0.1% 184
2025
Q2 		$3.48M Buy
6,682
+1,182
+21% +$660K 0.09% 194
2025
Q1 		$3.51M Buy
5,500
+1,721
+46% +$1.18M 0.14% 169
2024
Q4 		$2.66M Buy
3,779
+1,182
+46% +$992K 0.1% 195
2024
Q3 		$2.71M Sell
2,597
-1,055
-29% -$1.17M 0.11% 189
2024
Q2 		$3.84M Sell
3,652
-405
-10% -$393K 0.19% 126
2024
Q1 		$3.9M Buy
4,057
+359
+10% +$341K 0.22% 119
2023
Q4 		$3.26M Buy
3,698
+530
+17% +$436K 0.22% 114
2023
Q3 		$2.64M Sell
3,168
-10
-0.3% -$7.86K 0.25% 102
2023
Q2 		$2.25M Sell
3,178
-475
-13% -$366K 0.19% 129
2023
Q1 		$2.96M Buy
+3,653
New +$2.76M 0.25% 107

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vinva Investment Management's REGN Position: Q1 2026 in Review

Vinva Investment Management increased its Regeneron Pharmaceuticals (REGN) stake by 7% in Q1 2026, buying an estimated $744K and bringing the position to 14,862 shares worth $11.1M. The position accounts for 0.14% of the portfolio, ranked #166.

Vinva Investment Management first reported a position in REGN in Q1 2023 and has held it in 13 quarters since. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Vinva Investment Management held 14,862 shares of Regeneron Pharmaceuticals worth $11.1M as of Q1 2026.
  • Vinva Investment Management bought 972 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $744K.
  • Regeneron Pharmaceuticals made up 0.14% of Vinva Investment Management's portfolio in Q1 2026, its #166 holding.
  • Vinva Investment Management first reported a position in Regeneron Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Vinva Investment Management's 13F filing for Q1 2026, filed 14 May 2026.